Scoop has an Ethical Paywall
Dr Ken Taylor appointed Chief Executive
Living Cell Technologies Limited
CAN: 104 028 042
ASX: LCT
OTCQX: LVCLY
ASX ANNOUNCEMENT
Dr Ken Taylor appointed Chief Executive
8 July 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited today announced that Dr Ken Taylor has been appointed Chief Executive. Ken was appointed NTCELL Program Director in February and became Acting Chief Executive in April. He has been successful resuming patient recruitment in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease.
Dr Taylor joins LCT following a prestigious international career in both academia and business. He completed a postdoctoral fellowship in Pharmacology and Experimental Therapeutics at the Johns Hopkins University School of Medicine in Maryland, USA, and subsequently held a joint appointment in neurosciences at Princeton University and the Squibb Institute of Medical Research in Princeton, New Jersey. He joined Roche Australia and was soon promoted to the role of Medical Director, Australia; before becoming Managing Director of Roche New Zealand. In 1990, he was appointed Managing Director of the Roche UK affiliate and then transferred to Syntex in Palo Alto, California to convert the corporate pharmaceutical company to the Roche Bioscience Research Center. Prior to joining LCT, Dr Taylor was CEO of Antipodean Pharmaceuticals where he managed the Phase I and II studies of its lead compound in Parkinson’s disease. He holds Honours and Doctorate degrees in pharmaceutical chemistry and pharmacology from the University of Otago School of Medicine and completed a business management program at IMD in Lausanne, Switzerland.
Mr Roy Austin, Chairman of LCT, said “I am delighted to appoint Dr Taylor to the Chief Executive position because he brings such a depth of relevant scientific, regulatory and leadership knowledge and experience to the job.”
Dr Taylor said, “It is a very exciting time to be leading LCT with NTCELL for Parkinson’s disease in the clinic and the potential of our patented cell therapy to treat other neurological diseases such as Huntington’s, Alzheimer’s and motor neurone diseases.”
– Ends –
For further information: www.lctglobal.com
Business Canterbury: Urges Council To Cut Costs, Not Ambition For City
Wellington Airport: On Track For Net Zero Emissions By 2028
Landcare Research: ANZAC Gall Fly Release Promises Natural Solution To Weed Threat
NZ Anti-Vivisection Society: Auckland Rat Lovers Unite!
University of Canterbury: $1.35 Million Grant To Study Lion-like Jumping Spiders
Federated Farmers: Government Ends War On Farming
